Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: Comparison with cytokeratin 20

Journal of Urology

Volumn 174, Issue 6, 2005, Pages 2138-2143

  Wu, Xiuxian ^a   Kakehi, Yoshiyuki ^a,b   Zeng, Yu ^a   Taoka, Rikiya ^a   Tsunemori, Hiroyuki ^a   Inui, Mashashi ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Bladder; Bladder neoplasms; Cytokeratin 20; Neoplasm metastasis; Uroplakin II

Indexed keywords

BIOCHEMICAL MARKER; CYTOKERATIN 20; MESSENGER RNA; MOLECULAR MARKER; TUMOR MARKER; UNCLASSIFIED DRUG; UROPLAKIN; UROPLAKIN II;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER PATIENT; COMPARATIVE STUDY; CYSTECTOMY; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMEDIATE FILAMENT; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLING; TUMOR RECURRENCE;

EID: 27744542624     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000181214.32390.75     Document Type: Article

References (20)

1. Lerner, S. P., Skinner, D. G., Lieskovsky, G., Boyd, S. D., Groshen, S. L., Ziogas, A. et al: The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol, 149: 758, 1993
2. Vieweg, J., Whitmore, W. F., Jr., Herr, H. W., Sogani, P. C., Russo, P., Sheinfeld, J. et al: The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. The Memorial Sloan-Kettering Cancer Center experience. Cancer, 73: 3020, 1994
3. Madersbacher, S., Hochreiter, W., Burkhard, F., Thalmann, G. N., Danuser, H., Markwalder, R. et al: Radical cystectomy for bladder cancer today-a homogeneous series without neo-adjuvant therapy. J Clin Oncol, 21: 690, 2003
4. Stockle, M., Meyenburg, W., Wellek, S., Voges, G., Gertenbach, U., Thuroff, J. W. et al: Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol, 148: 302, 1992
5. Wu, X. R., Lin, J. H., Walz, T., Haner, M., Yu, J., Aebi, U. et al: Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem, 269: 13716, 1994
6. Wu, R. L., Osman, I., Wu, X. R., Lu, M. L., Zhang, Z. F., Liang, F. X. et al: Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. Cancer Res, 58: 1291, 1998
7. Yuasa, T., Yoshiki, T., Isono, T., Tanaka, T., Hayashida, H. and Okada Y.: Expression of transitional cell-specific genes, uroplakin Ia and II, in bladder cancer: detection of circulating cancer cells in the peripheral blood of metastatic patients. Int J Urol, 6: 286, 1999
8. Li, S. M., Zhang, Z.-T., Chan, S., McLenan, O., Dixon, C., Taneja, S. et al: Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. J Urol, 162: 931, 1999
9. Lu, J. J., Kakehi, Y., Takahashi, T., Wu, X. X., Yuasa, T., Yoshiki, T. et al: Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer. Clin Cancer Res, 6: 3166, 2000
10. Moll, R., Schiller, D. L. and Franke, W. W.: Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol, 111: 567, 1990
11. Miettinen, M.: Keratin 20: immunohistochemical marker for gastrointestinal, urothelial, and Merkel cell carcinomas. Mod Pathol, 8: 384, 1995
12. Retz, M., Lehmann, J., Roder, C., Weichert-Jacobsen, K., Loch, T., Romahn, E. et al: Cytokeratin-20 reverse-transcriptase polymerase chain reaction as a new tool for the detection of circulating tumor cells in peripheral blood and bone marrow of bladder cancer patients. Eur Urol, 39: 507, 2001
13. Rosenberg, R., Hoos, A., Mueller, J., Baier, P., Stricker, D., Werner, M. et al: Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J Clin Oncol, 20: 1049, 2002
14. Kummar, S., Fogarasi, M., Canova, A., Mota, A. and Ciesielski, T.: Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinoma. Br J Cancer, 86: 1884, 2002
15. Weber, T., Amann, K., Weckauf, H., Lacroix, J., Weitz, J., Schonfuss, T. et al: Detection of disseminated medullary thyroid carcinoma cells in cervical lymph nodes by cytokeratin 20 reverse transcription-polymerase chain reaction. World J Surg, 26: 148, 2002
16. Mostofi, F. K., Sobin, L. H. and Torloni, H.: Histological Typing of Urinary Bladder Tumours. Geneva, Switzerland: World Health Organization, 1973
17. Sobin, L. H. and Wittekind, C. H.: TNM Classification of Malignant Tumors, 5th ed. International Union Against Cancer. New York: Wiley-Liss, 1997
18. Seraj, M. J., Thomas, A. R., Chin, J. L. and Theodorescu, D.: Molecular determination of perivesical and lymph node metastasis after radical cystectomy for urothelial carcinoma of the bladder. Clin Cancer Res, 7: 1516, 2001
19. Funaki, N. O., Tanaka, J., Itami, A., Kasamatsu, T., Ohshio, G., Onodera, H. et al: Detection of colorectal carcinoma cells in circulating peripheral blood by reverse transcription-polymerase chain reaction targeting cytokeratin-20 mRNA. Life Sci, 60: 643, 1997
20. Wu, X. X., Kakehi, Y., Mizutani, Y., Terachi, T. and Ogawa, O.: Increased intracellular doxorubicin by anti-FAS monoclonal antibody: a mechanism that enhances the cytotoxicity in renal cell carcinoma cells. Urology, 57: 993, 2001